Table 1.
Summary of trials in Explorys and MarketScan for the PD case study. Emulated trials correspond to drugs with balanced treatment and control cohorts in both Explorys and MarketScan (percentage out of the tested drugs is shown in parentheses). An identified drug’s estimated effect reduces the prevalence of the corresponding PD outcome at FDR <0.05 in both Explorys and MarketScan.
| Outcome | Control cohort | Explorys and MarketScan trials and results |
||
|---|---|---|---|---|
| Tested drugs | Emulated trials (%) | Identified drugs | ||
| Dementia | random-drug | 223 | 183 (82%) | 0 |
| Dementia | ATC-L2 | 218 | 205 (94%) | 2 |
| Fall | random-drug | 259 | 219 (85%) | 0 |
| Fall | ATC-L2 | 247 | 228 (92%) | 1 |
| Psychosis | random-drug | 259 | 218 (84%) | 0 |
| Psychosis | ATC-L2 | 247 | 214 (87%) | 1 |
| Any outcome | random-drug | 259 | 259 (100%) | 0 |
| Any outcome | ATC-L2 | 247 | 247 (100%) | 4 |